Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Aptevo Therapeutics Inc. (NASDAQ: APVO).

Full DD Report for APVO

You must become a subscriber to view this report.


Recent News from (NASDAQ: APVO)

Aptevo Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference
SEATTLE, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the 30 th Annual Piper Jaffray Healthcare Conference on Tuesda...
Source: GlobeNewswire
Date: November, 20 2018 09:00
UAA, WFT, AKAM and SN among midday movers (10/30/2018)
Gainers:  Daxor (NYSEMKT: DXR ) +86% . Electro Scientific Industries (NASDAQ: ESIO ) +88% . Heidrick & Struggles International (NASDAQ: HSII ) +33% . Pioneer Energy Services (NYSE: PES ) +31% . Veracyte (NASDAQ: VCYT ) +29% . Under Armour (NYSE: UAA ) +26% . Chegg (NYSE: CHG...
Source: SeekingAlpha
Date: October, 30 2018 12:43
Aptevo Therapeutics: IXINITY Might Prove To Be A Never Expiring Option On The Company's Core Pipeline
Unfortunately, small and micro-cap stocks sometimes correct on no news in a risk-off environment, even when they have everything going for them. Such is the case for the recent correction of Aptevo Therapeutics ( APVO ). The stock is a gem in the micro-cap biotech space, because it's one o...
Source: SeekingAlpha
Date: October, 29 2018 15:34
Catalyst Biosciences: Highly Attractive Hemophilia Pipeline With Upcoming Catalysts, Yet Still Trading At Cash Value
Catalyst Biosciences (NASDAQ: CBIO ) is a clinical-stage biotech company focused on the treatment of hemophilia. Over the last year, its stock fluctuated widely, rallying from around USD 3 in August 2017 to above USD 30 in February 2017 before then dropping back to around USD 10 in June 2018 a...
Source: SeekingAlpha
Date: September, 07 2018 05:58
Aptevo Therapeutics Continues To Impress
Aptevo Therapeutics' ( APVO ) Q2'18 results were impressive. The company beat both on the top and the bottom line, with revenue coming in at $6.83M, an increase of 93.5% Y/Y, and EPS of $-0.58, $0.07 better than expected. However, the big surprise was the revenue growth of the company's ...
Source: SeekingAlpha
Date: August, 14 2018 10:28
Aptevo Therapeutics beats by $0.07, beats on revenue
Aptevo Therapeutics (NASDAQ: APVO ): Q2 EPS of -$0.58 beats by $0.07 . More news on: Aptevo Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 09 2018 09:03
Aptevo Therapeutics Reports Second Quarter 2018 Financial Results
Achieves Record IXINITY ® Net Revenue with 94% Increase in Year-Over-Year Quarterly Revenue Publishes and Presents New Data on Multiple ADAPTIR™ Bispecific Candidates Showing Robust Immune System Engagement and T-cell Activation Advances APVO436 Toward Clinical Dev...
Source: GlobeNewswire
Date: August, 09 2018 09:00
Aptevo Therapeutics Revises Term Loan Agreement With MidCap Financial; Reduces Cash Requirements by $18 Million
Defers Principal Repayments to February 2020 and Reduces Restricted Cash Covenant Aptevo to Announce Second Quarter 2018 Financial Results on August 9, 2018 SEATTLE, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on develo...
Source: GlobeNewswire
Date: August, 07 2018 09:00
Report: Developing Opportunities within athenahealth, W.R. Berkley, Air Products and Chemicals, DICK'S Sporting Goods, Aptevo Therapeutics, and Columbia Property Trust - Future Expectations, Projections Moving into 2018
NEW YORK, Aug. 06, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of athenahealth, Inc. (NASDAQ:ATHN), W.R. Berkley Corporation (NYSE:WRB), Ai...
Source: GlobeNewswire
Date: August, 06 2018 08:10
A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals
Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for...
Source: SeekingAlpha
Date: June, 16 2018 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-132.151.932.151.9283,459
2018-12-122.062.072.102.0050,109
2018-12-112.072.002.142.0063,338
2018-12-102.242.0412.242.04100,792
2018-12-072.272.212.3362.1038,777

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1321,49732,85865.4239Short
2018-12-122,66215,39417.2925Cover
2018-12-1116,57228,94857.2475Short
2018-12-1012,49332,41438.5420Short
2018-12-077,63916,32946.7818Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on APVO.


About Aptevo Therapeutics Inc. (NASDAQ: APVO)

Logo for Aptevo Therapeutics Inc. (NASDAQ: APVO)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: APVO)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 10 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 20 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 20 2018
      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: March, 21 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 13 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 13 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: January, 08 2018

       

       


      Daily Technical Chart for (NASDAQ: APVO)

      Daily Technical Chart for (NASDAQ: APVO)


      Stay tuned for daily updates and more on (NASDAQ: APVO)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: APVO)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in APVO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of APVO and does not buy, sell, or trade any shares of APVO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/